

**Company Name**

BioCubic LLC  
140 W Chestnut Ave.  
Monrovia, CA 91016

Chris Buser, PhD  
T (310) 307-3512  
[chris@biocubic.com](mailto:chris@biocubic.com)  
[www.biocubic.com](http://www.biocubic.com)

**Industry:** Life sciences  
(nanobiotechnology)

**Management/Founder Team:**

Christopher Buser, PhD  
Founder & CEO  
Christopher Thorn, MBA, CPA  
CFO

**Seeking roles:**

Chief Technology Officer  
Chief Medical Officer  
VP Sales & Marketing

**Advisors:**

Steven Gordon, JD (legal)  
COO Equilibre Biopharma  
Marc Baum, PhD (org.chem.)  
CEO Oak Crest Institute of Science  
John Moss, PhD (spectroscopy),  
Senior Faculty Oak Crest Inst. of Science  
Paul West, PhD, MBA  
(atomic force microscopy),  
President AFMWorkshop Inc.

**Funding to Date:** \$83,000

Founder: \$5,000

Members: \$78,000

**Funding Sought:**

\$750,000 for R&D, IP filing,  
salaries, operating costs

**IP:** Nanohistology (provisional  
filed), trade secrets

**Legal:**

Marshall, Gerstein & Borun LLP

**Company Description / Background:**

BioCubic's mission is to make molecular resolution imaging data accessible to customers in biomedical research, clinical trials, and disease diagnostics.

**Problem:**

Many diseases manifest themselves in tissues on a molecular scale, yet most researchers and clinicians do not have access to the corresponding nanoscale imaging data, limiting the impact of research and diagnostics. Existing imaging technologies are unworkable for the large sample numbers required for preclinical and clinical projects.

**Solution:**

Nanohistology (patent pending) uses atomic force microscopy to generate molecular resolution images of tissue samples in large experimental groups. This automated, parallel processing and imaging technology allows the creation of high-resolution image datasets (incl. AI applications) at a cost comparable to traditional histology.

**Market:**

Through product development, BioCubic will sequentially enter the disease research market (relevant NIH centers, \$35B), add the clinical trials market (\$38B), and the histopathology market (\$24B) with imaging and data products. We serve a global client base through simple courier shipping of samples.

**Competition / Competitive Advantage:**

Only niche providers deliver molecular resolution data with electron microscopy (high cost, low throughput). Most activity is in histology (automation, AI for histopathology), the gold standard but at 1,000x lower, cellular resolution. BioCubic's unique value proposition is the efficient generation of molecular-resolution image data for large sample numbers.

**Traction and Progress:**

We are preparing to market characterization and prototype nanohistology services to established early adopters who have agreed to be ambassadors. An NSF phase 1 SBIR grant has been submitted and is in revision.

**Future Plans and Milestones:**

We will sell services and complete the MVP in FY1. Automation of the MVP in FY2 will allow us to scale (large sample batches for clinical trials), add a protein localization feature in FY3, and generate image databases for key tissues as a data subscription product in FY4. Once nanohistology is validated we will begin marketing a nanopathology platform for healthcare diagnostics in FY5.

**Financial Forecast:**

BioCubic will immediately begin to generate revenue, with break even in late FY1, and expand into new market segments through the development of new products, scaling through efficiency and automation.

(in thousands)	FY1	FY2	FY3	FY4	FY5
Net Revenue	\$203	\$1,135	\$6,835	\$21,726	\$51,392
Operating Expenses	\$208	\$837	\$2,185	\$4,841	\$8,461
<b>Operating Income</b>	<b>(\$46)</b>	<b>\$92</b>	<b>\$4,067</b>	<b>\$15,372</b>	<b>\$40,151</b>
Capital Expenses	\$50	\$400	\$800	\$1,000	\$2,400